Carcinoma, Non-Small-Cell Lung, Immune-Related Adverse Events
Conditions
Keywords
PD-1 inhibitor, Nivolumab, Pembrolizumab, Atezolizumab, Immune-Related Adverse Events, Carcinoma, Non-Small-Cell Lung
Brief summary
The objective of our study is to assess the risk of immune-related adverse events associated with PD-1 inhibitors use compared to standard chemotherapy use in patients with non small cell lung cancer, using nationwide healthcare database.
Detailed description
This observational, retrospective cohort study will evaluate the risk of immune-related adverse events associated with PD-1 inhibitors use compared to standard chemotherapy use in patients with non small cell lung cancer, using nationwide healthcare database. PD-1 inhibitors will be defined as nivolumab, pembrolizumab, and atezolizumab. Standard chemotherapy will be defined as cytotoxic chemotherapy or tyrosine kinase inhibitors (epidermal growth cell receptor (EGFR) and anaplastic lymphoma kinase (ALK) inhibitors). The investigators will assess exposure on the cohort entry using the intention-to-treat approach with the 6-month exposure risk window from the first PD-1 inhibitor prescription to avoid bias from informative censoring. Immune-related adverse events will be defined by using pre-specified algorithms using diagnosis and corticosteroid prescription records (high dose of oral corticosteroids, defined as ≥ 30 mg/day, or systemic corticosteroid injection) to reduce outcome misclassification. The investigators will use a multivariable Cox proportional hazard model to estimate hazard ratio (HR) and 95% confidence intervals (CI). The model will be adjusted for pre-existing autoimmunity, history of lung cancer surgery, radiation therapy, tyrosine kinase inhibitor use, and previous systemic corticosteroid use. All analyses will be undertaken using SAS 9.4 (SAS Institute Inc., Cary, NC, USA).
Interventions
DRUGPD-1 inhibitor
PD-1 inhibitors are a group of checkpoint inhibitors being developed for the treatment of cancer. PD-1 and PD-L1 are both proteins present on the surface of cells. Immune checkpoint inhibitors such as these are emerging as a front-line treatment for several types of cancer. The investigators will include nivolumab, pembrolizumab, and atezolizumab as PD-1 inhibitors as these drugs are reimbursed by health authority of South Korea.
Chemotherapy is a type of pharmacotherapy for cancer, that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen. The investigators will include cytotoxic chemotherapy and tyrosine kinase inhibitors (epidermal growth cell receptor (EGFR) and anaplastic lymphoma kinase (ALK) inhibitors).
Sponsors
Ministry of Food and Drug Safety, Korea
Sungkyunkwan University
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Individuals who were diagnosed with lung cancer (ICD-10: C33-C34) between 2017 and 2018.
Exclusion criteria
* Individuals less than 18 years of age * Individuals received any systemic anticancer therapies in 2007 * Having no records of prescription of PD-1 inhibitors or standard chemotherapy at least once between 2017 and 2018 * Individuals received treatments indicated for small cell lung cancer (etoposide, ifosfamide, irinotecan, belotecan, and topotecan) on or before the first date of standard chemotherapy to restrict study subjects to patients with non small cell lung cancer only.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Hazard ratio for immune-related adverse events | August 2017 to December 2018 | The ratio of hazard rates of immune-related adverse events in PD-1 inhibitor users vs. standard chemotherapy users |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Hazard ratio for eleven subdivided groups of immune-related adverse events by organ class | August 2017 to December 2018 | The ratio of hazard rates of eleven subdivided organ-specific immune-related adverse events (pulmonary, endocrine, cardiovascular, gastrointestinal, hepatic, muscluoskeletal, neurological, ocular, renal, skin, and hematologic) in PD-1 inhibitor users vs. standard chemotherapy users |
Contacts
Primary ContactYeon-Hee Baek
Outcome results
None listed